Richard B Warren

..Understanding the key risk factors for CLCI may help physicians identify patients who are more vulnerable to the cumulative impact of psoriasis, resulting in more appropriate treatment decisions earlier in the disease course...

..Many autoimmune diseases share common susceptibility loci suggesting similar underlying cellular mechanisms involved in disease expression...

..There are few reports of the practical use of adalimumab outside of a clinical trial setting and, to our knowledge, none from the U.K...

..A similar and more detailed review to this appeared in the 2009 Annual Evidence Update on Psoriasis from NHS Evidence - Skin Disorders in November 2009...

..In this article, we discuss approaches that may be utilized to refine these existing therapies and examine future therapeutic targets for biological therapies...

..Previous studies in patients with either rheumatoid arthritis or psoriasis suggest that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the drug...

..The aim of this review is to critically assess the relative effectiveness and tolerability of available topical therapies for this problematic condition and provide recommendations for selection of treatment...

..However, to date, there are few reports of the practical use of these therapies outside of the trial setting and, to our knowledge, none from a U.K. cohort of patients with psoriasis...

..Furthermore, the potential for personalized methotrexate use by application of modern pharmacogenetics and pharmacokinetics may ensure its place as a first-line agent for the treatment of psoriasis for the foreseeable future...

..2 (95% confidence interval: 1.3-3.6; P=0.001) for developing toxicity to methotrexate. These data indicate that knowledge of SNPs in genes relevant to methotrexate efflux may be important in selecting patients suitable for this therapy...

..Given this intriguing evidence, association to this gene was investigated in large collections of PsA and PsV patients and healthy controls...

..Ideally, cyclosporine should be used for short courses of 3 to 4 months duration, within which it provides excellent disease control. Close assessment of renal function and blood pressure is essential...

..The currently available safety data are on the whole reassuring, although ongoing vigilance remains central to the detection of rare or late sequelae...

..These findings collectively identify a novel psoriasis susceptibility gene, with a putative role in the regulation of immune responses...

..This condition is rarely reported; however, as biopsy is sometimes not performed, it may be underrepresented. We present a further histopathologically proved instance of this entity, with discussion of the differential diagnosis...